Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02

Targovax Granted EU Patent for Mutant-RAS Neoantigen Platform 2nd Generation Product TG02

June 19, 2018 Provides IP protection of TG02 in Europe until 09.12.2033 OSLO, Norway, June 19, 2018 /PRNewswire/ — Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), is a clinical stage company focused on developing and commercializing immune activators to target hard to